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APOBEC3G (A3G) is a cellular protein that inhibits HIV-1 infection through virion
incorporation. The interaction of the A3G N-terminal domain (NTD) with RNA is essential
for A3G incorporation in the HIV-1 virion. The interaction between A3G-NTD and
RNA is not completely understood. The A3G-NTD is also recognized by HIV-1 Viral
infectivity factor (Vif) and A3G-Vif binding leads to A3G degradation. Therefore, the
A3G-Vif interaction is a target for the development of antiviral therapies that block HIV-1
replication. However, targeting the A3G-Vif interactions could disrupt the A3G-RNA
interactions that are required for A3G’s antiviral activity. To better understand A3G-RNA
binding, we generated in silico docking models to simulate the RNA-binding propensity
of A3G-NTD. We simulated the A3G-NTD residues with high RNA-binding propensity,
experimentally validated our prediction by testing A3G-NTD mutations, and identified
structural determinants of A3G-RNA binding. In addition, we found a novel amino acid
residue, I26 responsible for RNA interaction. The new structural insights provided here will
facilitate the design of pharmaceuticals that inhibit A3G-Vif interactions without negatively
impacting A3G-RNA interactions.
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INTRODUCTION
APOBEC3G (A3G), a member of the cellular cytidine deaminase APOBEC3 superfamily, exhibits
anti-HIV activity primarily by inducing G-to-A hypermutation in the viral cDNA (Wedekind
et al., 2003; Conticello et al., 2007; Conticello, 2008; Desimmie et al., 2016). The interaction of
A3G with the HIV-1 nucleocapsid (NC) domain of Gag is necessary for A3G encapsidation into
HIV-1 virions in virus producing cells (Luo et al., 2004; Schäfer et al., 2004; Svarovskaia et al.,
2004; Zennou et al., 2004; Khan et al., 2005; Wang et al., 2007). A3G deaminates nascent cDNA
strands generated by reverse transcription and potently restricts HIV-1 replication in target cells.
HIV-1 Viral infectivity factor (Vif) counteracts the A3G-mediated antiviral activity by inducing
degradation of A3G through the ubiquitin-proteasome pathway (Harris and Liddament, 2004;
Izumi et al., 2008, 2009).
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A3G requires RNA to interact with the NC domain of Gag
for its encapsidation in the virion (Luo et al., 2004; Schäfer
et al., 2004; Svarovskaia et al., 2004; Zennou et al., 2004). It has
been shown that several RNAs, including the HIV-1 genomic
RNA, the cellular Y RNAs, and 7SL RNA participate in these
interactions (Khan et al., 2005; Wang et al., 2007). However, the
structural basis of these interactions is controversial (Bach et al.,
2008; Izumi et al., 2013; Apolonia et al., 2015). A3G has two
homologous domains (Jarmuz et al., 2002; Wedekind et al., 2003;
Navarro et al., 2005; Larue et al., 2009). The N-terminal domain
(A3G-NTD), consisting of residues 1-200, is catalytically inactive
but indispensable for Vif-interaction and A3G encapsidation
(Bogerd et al., 2004; Mangeat et al., 2004; Schrofelbauer et al.,
2004; Xu et al., 2004; Navarro et al., 2005; Iwatani et al., 2006;
Huthoff and Malim, 2007; Izumi et al., 2010; Feng and Chelico,
2011; Bélanger and Langlois, 2015) and is also involved in the
association with viral and cellular RNAs (Wang et al., 2007; Bach
et al., 2008; Bulliard et al., 2009; Friew et al., 2009; Huthoff et al.,
2009; Chelico et al., 2010; Lavens et al., 2010; Zhang et al., 2010;
Shlyakhtenko et al., 2011; Uyttendaele et al., 2012; Apolonia et al.,
2015; Bélanger and Langlois, 2015). Several groups have shown
that amino acids 22-136 of the A3G-NTD are required for A3G-
RNA interaction, A3G encapsidation, and A3G oligomerization
(Huthoff et al., 2009; Bélanger and Langlois, 2015). Specifically,
two tryptophan residues at position 94 and 127, and residues
R24, S28, R30, R122, Y124, and F126 have been determined to
be involved in A3G-RNA interactions (Table 1) (Huthoff and
Malim, 2007; Bach et al., 2008; Bulliard et al., 2009; Huthoff et al.,
2009; Zhang et al., 2010; Bélanger and Langlois, 2015).
Little is known about the molecular structure of the A3G-
NTD and RNA complex. HIV-1 Vif mediates A3G degradation
via the ubiquitin-proteasomal pathway (Sheehy et al., 2002;
Harris et al., 2003; Mangeat et al., 2003; Zhang et al., 2003).
Importantly, the A3G-Vif interaction is a valuable target for
the design of novel antiviral molecules. In this regard, some of
the previously identified A3G-RNA interacting residues, Y124
or W127 (Huthoff and Malim, 2007; Huthoff et al., 2009),
are also necessary for the interaction of A3G with HIV-1 Vif,
suggesting that the A3G-NTD binding surfaces for RNA and
Vif may overlap (Uyttendaele et al., 2012). Therefore, better
defining the A3G-RNA binding sites will aid the rational design
of A3G-Vif inhibitors that do not exert off target effects on
A3G-RNA binding.
Recently, Kouno et al. revealed the human A3G-NTD
structure by solution NMR. For this purpose, they engineered
a soluble form of the human A3G-NTD by introducing several
mutations and deletions, resulting in a sequence identity of 80%
with the wild-type (WT). Interestingly, this soluble A3G-NTD
mutant was not packaged into virus particles (Kouno et al., 2015),
suggesting that it could no longer interact with the target RNA.
However, because of the considerably high sequence identity,
the NMR structures are a useful tool for in silico modeling
studies. Here, to account for A3G flexibility in simulation of RNA
binding, we used a novel approach by generating an in silicoA3G-
RNA docking model based on ten A3G-NTD NMR structure
snapshots. Further, we validated the accuracy of our model
in vitro and ex vivo using full-length A3G alanine mutation
analysis. In addition, we developed a second homology model
based on the non-human primate A3G-NTD crystal structure
(Xiao et al., 2016), and predicted its RNA docking patterns.
These docking models mostly provided similar RNA association
parameters and allowed us to identify A3G I26 as a novel residue
involved in A3G-RNA association.
MATERIALS AND METHODS
Plasmid Construction and Cell Culture
We constructed an expression vector of hemagglutinin
(HA)-tagged human A3G, pcDNA3/HA-A3G, as previously
described (Kobayashi et al., 2004) that we used for single
site A3G mutations (Y22E, I26A, S28A, R29A, R30A,
Y86A, R122A, Y124A, and E259Q) generated with the
QuickChange XL site directed mutagenesis kit (Stratagene).
The C-terminal EYFP-tagged A3G expression plasmids
were generated by inserting the above mentioned A3G
fragments amplified by PCR into the NheI and KpnI site of
pEYFP-N1 vector (Clontech). A 3xFLAG synthesized DNA
was inserted between the A3G and EYFP coding regions
(pA3G-3xFLAG-EYFP). For visualizing virus particles, we
used an HIV-1 based construct that expresses the fusion
protein Gag containing the mCherry fluorescent protein
with HIV-1 protease recognition sequence between MA
and CA (imCH) as previously reported (Hübner et al.,
2007). A stop codon was inserted into the vif region and
the env gene was frame-shifted to be deleted in the imCH
vector (imCH1Vif1Env). Adherent HEK293T cells or non-
adherent M8166 cells were cultured in 10% Fetal Calf Serum
of Dulbecco’s Modified Eagle’s Medium or RPMI Medium,
respectively (Kobayashi et al., 2004). Cells were maintained at
37◦C with 5% CO2.
Molecular Modeling of the A3G N-Terminal
Domain
Homology Modeling
The original amino acid sequence of human A3G-NTD (1–200)
was aligned to either the soluble form of human A3G-NTD
(PDBID: 2mzz) (Kouno et al., 2015) or the crystal structure
of a non-human primate A3G (PDBID: 5k81) (Xiao et al.,
2016) and rendered in 3D by Spanner (Lis et al., 2011). Ten
NMR structures and one crystal structure were used for model
building followed by RNA-binding site prediction with the
aaRNA algorithm (Li et al., 2014) or DNA-binding site prediction
with the aaDNA algorithm.
RNA Docking Simulations
The ESPResSo (Limbach et al., 2006) molecular dynamics
package was used for all coarse-grained molecular dynamics
(CGMD) simulations. To simplify the model, we represented
each amino acid and nucleotide residue as single-beads and
fixed each protein structure during the simulation. A soft core
potential was introduced between protein and nucleotides so that
the nucleotide could not enter the core region of the protein.
The binding propensity (BP) of each amino acid was used as
an additional contact potential to sample reliable RNA or DNA
binding conformations. While the RNA BP was predicted by a
counterpart network model based on RNA-binding proteins, the
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TABLE 1 | Amino acid residues in A3G-NTD reportedly involved in RNA association and their binding propensity (BP) and contact frequency (CF) of RNA or DNA as
determined in our study.
aaRNA aaDNA
Soluble A3G model Rhesus model Soluble A3G model
Residue RNAs References BP CF BP CF BP CF
W94L hY1, hY3, 7SL, and Alu
Bulliard et al., 2009
High High Moderate High High High
W127A Low High Moderate Moderate High High
S28E but not S28A hY1 and hY3, but not 7SL
nor Alu
Moderate High High High High High
Y124A hY1 and hY3, but not 7SL
nor Alu
High High High High High High
F126L hY1, 7SL, and Alu, but not
hY3
Moderate High Moderate Moderate High High
W94A hY1, hY3, 7SL, and Alu Bélanger and Langlois, 2015 High High High High High High
W127A Low High Moderate Moderate High High
R24A
hY1, hY4, and 7SL Huthoff et al., 2009
Low High Moderate Moderate Moderate High
W127A Low High Moderate Moderate High High
R30A High High High High High High
W127A 7SL Bach et al., 2008 Low High Moderate Moderate High High
Y91A
7SL Zhang et al., 2010
Low Low Low High Moderate Moderate
R122A High High Moderate Moderate High High
L123A Moderate High Low Low Moderate High
Y124A High High High High High High
Y125A Moderate High High Moderate High Moderate
F126A Moderate High Moderate Moderate High High
W127A, F, L, or Y Low High Moderate Moderate High High
aaRNA aaDNA
Soluble A3G Rhesus model Soluble model
BP CF BP CF BP CF
Low <0.060 <0.020 <0.010 <0.008 <0.013 <0.040
Moderate 0.060–0.160 0.020–0.220 0.010–0.102 0.008–0.536 0.013–0.133 0.040–0.200
High 0.160< 0.220< 0.102< 0.536< 0.133< 0.200<
DNA BP was predicted by an artificial neural network model
based on DNA-binding proteins. For each soluble A3G model,
we randomly distributed 100 non-specific 5-mer RNA or DNA
molecules around the protein to initialize the system. A total
of 10,000 snapshots were stored for each soluble model and
grouped by progressive clustering with 10Å as a threshold. The
clusters were sorted from higher to lower scores, and the top
five clusters were investigated further. The contact frequency
(CF) of each amino acid was calculated based on the top five
clusters from each soluble model. For the single crystal A3G
model, a total of 100 clusters were used for CF calculation of each
amino acid.
Statistical Analysis of BP and CF
Because both the BP and CF of each amino acid do not
follow normal distributions, we calculated the average, standard
deviation (SD), median, and quartiles of the all BP and CF.
High values were defined as being greater than the third
quartile, while low values were defined as being less than the
first quartile.
Single-Virion Imaging Analysis
To visualize the encapsidation of EYFP-tagged A3G or its
mutants in virions, pA3G-3xFLAG-EYFP was co-transfected
with imCH1Vif1Env in HEK293T cells (3.5 million per
10 cm dish) with the PEI transfection reagent (GE Healthcare).
The virus-containing supernatant was harvested at 24 h post-
transfection, filtered through 0.45µm pore size sterile cellulose
membrane and concentrated up to 20-fold by ultracentrifugation
through a 20% sucrose cushion at 25,000 rpm for 90min
at 4◦C (CP65; Hitachi Koki Co., Ltd.). The concentrated
virus supernatant (0.5 µL) was briefly mixed with 200 µL
Hank’s Balanced Salt Solution (HBSS) (+) without Phenol Red
(Wako) and mounted onto 8-well glass bottom chamber slides
(Matsunami), then incubated overnight at 4◦C. Images of virions
were acquired with an A1R Confocal Microscope (Nikon).
mCherry was used to identify virus particles and EYFP was used
to detect incorporated A3G protein. Images were first exported
using the NIS-Elements software (Nikon) and representative
images were processed with Fiji, an image processing package in
ImageJ (NIH). A binary image of the mCherry and EYFP signals
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was generated to count the positive puncta. A3G encapsidation
efficiency was calculated as percentage of mCherry positive
signals that co-localized with the EYFP signal within a 3-pixel




Cells were lysed using RIPA buffer (Wako) supplemented
with protease inhibitor cocktail (Sigma-Aldrich) and the
supernatants were collected after centrifugation. Polyacrylamide
gel electrophoresis and protein transfer to PVDF membranes
(Immobilon, Millipore) were followed by hybridization with
primary antibodies. Blots were probed with rabbit anti-HA
(Sigma-Aldrich), mouse anti-Vif (NIH AIDS Reagent Program),
and mouse anti-GFP (Thermo Fisher Scientific) primary
antibodies overnight at 4◦C. HRP-conjugated anti-mouse or
rabbit IgG antibodies (GE Healthcare) were used as secondary
antibodies. Western blot images were obtained with x-ray films.
EYFP fluorescence intensity in the cell lysates was measured with
a plate reader (Perkin Elmer, 2030 ARVO X3).
qPCR Assay
A3G and its derived mutants (Y22E and R122A) were
immunoprecipitated with anti-HA antibody conjugated Protein
A beads from cell lysates extracted from transfected HEK293T
cells. After immunoprecipitation, A3G associated RNAs were
purified with the High Pure RNA extraction kit (Roche). The
concentration of purified RNA was measured by a NanoDrop
ND-1000 Spectrophotometer and adjusted to the total RNA
amount prior to the reverse transcriptase (RT) reaction. The RT
product was obtained by TaKaRa PrimeScript 1st strand cDNA
Synthesis Kit. The RNA denaturing process was performed at
65◦C for 5min, followed by 4◦C for 10min with 1 µL Random
hexamers and 1 µL dNTP mix. The denatured RNAs were then
reverse-transcribed with 4 µL 5xPrimeScript Buffer, 20 units
RNase Inhibitor (40 U/µL), 200 units PrimeScript RTase, and
4.5 µL RNase free water. The RT reaction was performed at
30◦C for 10min, 42◦C for 60min, 95◦C for 5min and then 4◦C
overnight. A Real-Time PCR instrument, Thermal Cycler Dice
Real Time System TP800 (TaKaRa) was used for monitoring PCR
amplifications. All primers were synthesized by SIGMA. qRT-
PCR was performed using SYBR green. Each reaction mixture
contained 0.5µL of forward and reverse primers (10µM), 10µL
of THUNDERBIRD SYBR qPCR Mix (TOYOBO), 7µL of
RNase-free water, and 2µL of template cDNA. The reactions
were performed under the following conditions: 94.0◦C for 10 s,
followed by 40 cycles of 95◦C for 5 s and 60◦C for 30 s, for the final
step. Single peaks in the melting-curve analysis indicated specific
amplicons. Primer sequences used in these assays were previously
published (Wang et al., 2007). Each Y and 7SL RNA association
to A3G was compared to the mock sample whose level was set
to 1. Three independent experiments were performed. P-values
were calculated relatively to the A3GWT.
Escherichia Coli Mutation Assay
The BW310 strain of E. coli was transformed with pTrc-His A
based Isopropyl β-D-1-thiogalactopyranoside (IPTG)-inducible
A3G expression vectors or the empty vector (Petersen-Mahrt
et al., 2002). Individual colonies were picked and grown to
saturation in LB medium containing 50µg/mL ampicillin and
1mM IPTG. Appropriate dilutions were spread onto agar plates
containing either 50µg/mL ampicillin or 100µg/mL rifampicin
and incubated overnight at 37◦C. Mutation frequencies were
recorded as the number of rifampicin-resistant colonies per
106 viable cells, which were enumerated using the ampicillin
containing plates. Colony counts were recorded in this manner
for 6 rifampicin- and 2 ampicilin-containing plates for each
construct. The average colony count for A3GWTwas set to 100%
and all other scores were normalized to this value.
Single-Round Infection Assay
The VSV-G pseudotyped HIV-1-1Vif luciferase reporter viruses
with A3G or its mutants were produced by co-transfection of
pNL4-3/1env1vif-Luc and pVSV-G with the A3G expression
vector (pcDNA3/HA-A3G) in HEK293T cells as previously
described (Shindo et al., 2003; Kobayashi et al., 2004). The target
M8166 cells were infected with reporter viruses normalized by
p24 amount, which was measured by HIV Type 1 p24 Antigen
ELISA (ZeptoMetrix). The infectivity was measured by luciferase
activity and values were normalized to the infectivity of the virus
produced in the absence of A3G expression.
RESULTS
Homology Model Structure Based
Calculation of the A3G-RNA Binding
Propensity
In the present study, we used a 3D structural model of A3G-NTD
WT (1-200) based on the previously published NMR solution
structure snapshots of a soluble mutant A3G-NTD (PDBID:
2mzz) (Lis et al., 2011; Kouno et al., 2015) (Figure 1A). In
order to consider the flexibility of the protein, we built in silico
models employing each of the ten NMR structure snapshots
available, followed by RNA-binding site predictions generated
by the RNA binding site predictor, aaRNA (Li et al., 2014). The
aaRNA predictor can generate accurate and robust RNA binding
propensities (BP) for each residue based on both sequence
and structure features, and is suitable for studying proteins
like A3G that have flexible potential binding loops to interact
with RNA (Supplementary Figure 1). The aaRNA algorithm
predicted residues that show high average RNA BP (Figure 1B
and Supplementary Figure 1). We also built another structure
model of humanA3G-NTDbased on the crystal structure of non-
human primate A3G-NTD (Xiao et al., 2016) and calculated the
BP for each residue (Figure 1C and Supplementary Figure 2).
Evaluation of the A3G RNA Binding
Propensity by Mutational Analysis of the
A3G-NTD R122 Residue
To experimentally validate the in silico RNA binding predictions,
we generated an in vitro mutant of the residue R122. As a
positively charged residue, R122 is involved in RNA interactions
(Zhang et al., 2010), and is predicted to have a high RNA
BP (Figure 1B). As a control, we mutated Y22, which has a
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FIGURE 1 | Construction of the A3G-NTD homology model. (A) Homology model of wild-type human A3G-NTD based on the soluble A3G-NTD NMR structure
(PDB:2mzz) generated by the structural homology modeling program, Spanner. The binding propensities (BP) of residues on the A3G surface are color coded as
indicated by the scale bar (high BP, red; low BP blue). The right panel shows the structure model in the left panel rotated 180 degrees. The selected residues that were
tested in this study or have been reported to be involved in RNA association or Vif interaction are indicated by arrows. (B) RNA-binding propensity (BP) of selected
residues from Supplementary Figure 1 predicted by aaRNA. Box plots show the BP distribution for ten models based on soluble A3G NMR structures; error bars
represent standard deviation. (C) BP of selected residues from Supplementary Figure 2. The bar graph shows the BP of a single model of non-human A3G crystal
structure (PDB:5k81).
low predicted BP (Figures 1B,C). Mutants R122A and Y22E
in the full length A3G protein were examined to evaluate
the A3G RNA-binding affinity. We immunoprecipitated A3G
and performed qRT-PCR with primers to detect the host Y
RNAs, previously reported to associate with A3G (Wang et al.,
2007). Although all cellular RNAs analyzed, except for hY5,
associated strongly with the A3G-WT and the Y22E mutant,
the levels associating with the R122A were significantly lower
(Figure 2A). We then assessed the efficiency of encapsidation
of these A3G mutants into HIV-1-1Vif virus particles by
single virion visualization (Figure 2B) (Hübner et al., 2007;
Chen et al., 2009; Burdick et al., 2010; Izumi et al., 2013).
A3G-WT and the Y22E mutant were detected in 42.4% and
43.1% of virions, respectively, whereas the R122A mutant
was detected in only 4.2% of virions (Figure 2C), confirming
previous observations (Huthoff and Malim, 2007). We lysed
cells after harvesting the virus supernatant and measured the
EYFP fluorescence with a plate reader to verify the cellular
expression level of A3G mutants in virus producer cells.
The GFP fluorescence intensity has been previously correlated
with protein expression of GFP-tagged A3G in producer cells
(Matsui et al., 2014). We found that these point mutations
did not affect cellular expression of A3G as quantified by
their EYFP signal intensities (Figure 2D). These results are
consistent with previous reports showing that A3G virion
encapsidation is mediated by A3G-RNA association (Luo
et al., 2004; Schäfer et al., 2004; Svarovskaia et al., 2004;
Zennou et al., 2004).
Functional Evaluation of the A3G R122 Mutant
It has previously been suggested that the RNA-binding capacity of
A3G correlates with its dimerization (Huthoff and Malim, 2007;
Chelico et al., 2010; Bélanger et al., 2013). Therefore, to examine
the contribution of R122A dimerization to RNA association, we
performed co-immunoprecipitation experiments of HA-tagged
R122A mutant with GFP tagged A3G WT. We confirmed that
the R122A mutant is unable to form an RNA-mediated dimer
(Figure 3A and Supplementary Figure 3). We also performed a
single-round infection assay to evaluate the antiviral activity of
A3G-R122A mutant. We found that A3G WT and the virion-
encapsidated mutant, Y22E, inhibited HIV-1-1Vif infection
(Figure 3B). As expected, the R122A mutant, which was unable
to dimerize (Figure 3A) or efficiently package into virions
(Figure 2C), showed little antiviral activity confirming previous
observations (Zhang et al., 2007). We next evaluated the
deaminase activity of these A3G mutants by using a bacterial
mutation assay. Unlike the E259Q deaminase-defective mutant
(Schumacher et al., 2008), the deaminase activities of the Y22E
and R122A mutants were not statistically significantly different
from the A3G WT deaminase activity (Figure 3C). Altogether,
these data showed that the loss of antiviral activity for the R122A
mutant was primarily due to its defective virion incorporation.
Because the Vif binding region partially overlaps with the
RNA interaction domain of A3G-NTD, we further investigated
the sensitivity of the R122A mutant toward Vif-mediated
degradation. Co-immunoprecipitation of A3G and Vif revealed
that the R122A mutation impaired the A3G-Vif interaction
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FIGURE 2 | Analysis of the A3G-NTD R122 residue for RNA association and incorporation in HIV-1 virions. (A) Selective interaction of A3G and its mutants with
cellular RNAs, 7SL and Y RNAs. Analysis of the interactions between cellular RNAs with HA-A3G by qRT-PCR is shown. Cell lysates from transfected HEK293T cells
were immunoprecipitated with anti-HA antibody conjugated to agarose beads. RNAs were extracted from the co-immunoprecipitated samples and analyzed by
qRT-PCR using primers specific for Y1, Y3, Y4, Y5, and 7SL RNA. Mean values and standard deviations of three independent qPCR reactions are shown for each
condition. The level of the mock sample is set to 1. The asterisks indicate statistically significant decreases compared to the amount of cellular RNAs associated with
A3G WT calculated by student t-test (p < 0.05). (B) Packaging efficiency of A3G mutants into HIV1-1Vif virions determined by single virion imaging analysis.
Representative images of virus particles labeled with Gag (mCherry) containing EYFP or EYFP-tagged A3G are shown. The left two panels show the original image,
and the right three panels show the binary image constructed with an in-house MatLab script. EYFP expression plasmid was used as a negative control. White arrows
indicate the mCherry particles that contain EYFP signals. (C) Packaging efficiency calculated by the percentage of Gag (mCherry) particles containing EYFP signal.
The number of EYFP positive particles (upper) and total Gag-mCherry particles (lower) counted from three independent experiments is shown above the graph. Error
bars represent standard deviations for three independent experiments. Asterisks indicate statistically significant decreases compared to EYFP-tagged A3G (student
t-test, p < 0.05). (D) Intracellular expression of A3G and its derived mutants in virus producer cells determined by measuring EYFP intensity.
(Figure 3D and Supplementary Figure 4). In addition, co-
transfection of A3G and Vif without proteasome inhibitor
treatment confirmed that A3G-R122A is resistant to Vif-
mediated degradation (Figure 3E and Supplementary Figure 5).
These data confirmed that residues in the A3G-NTD involved in
the interaction with RNA are also involved in the interaction with
Vif (Uyttendaele et al., 2012).
A3G Binding Propensity to RNA by Single-Virion
Analysis
In order to confirm our RNA-binding prediction, we further
tested the contribution of residues S28, R30, and Y124 that are
known determinants of A3G-RNA association (Bulliard et al.,
2009; Huthoff et al., 2009; Zhang et al., 2010) and had modest
to high BP in our model (Figures 1B,C). In addition to these
previously reported RNA-binding residues, we also tested I26,
R29, and Y86, which also showed modest to high BP in our
prediction (Figures 1B,C). These residues were not previously
reported to contribute to RNA association so they were tested in
the present study through mutagenesis. We made single alanine
substitution mutants in I26, S28, R29, R30, Y86, or Y124 and
tested their virion incorporation efficiency. Like R122, mutation
of the I26, S28, R30, and Y124 residues significantly disrupted
A3G virion incorporation. On the other hand, mutants R29A
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FIGURE 3 | Functional analysis of the A3G-NTD R122 mutant. (A) Co-immunoprecipitation of HA-tagged R122A mutant with GFP tagged A3G WT. GFP-tagged A3G
and HA-tagged R122A mutant were transiently co-expressed in HEK293T cells. Cell lysate and immunoprecipitated complexes were loaded on SDS-PAGE followed
by immunoblot analysis using HA- and GFP-specific antibodies. HA-tagged A3G co-transfected with GFP alone served as a control for nonspecific binding of GFP to
HA-A3G (lane 1) and GFP-tagged A3G alone served as a control for nonspecific binding to anti-HA beads (lane 2). The combination of HA-A3G-WT or –R122A
mutant with GFP-A3G-WT is shown in lane 3 or lane 4, respectively. (B) Single-cycle infectivity of HIV-1 WT or 1Vif viruses produced in the presence of WT or mutant
A3G proteins was measured in relative luciferase units and presented as percent infectivity relative to mock. The empty vector control is shown as mock. Three
independent experiments were averaged and error bars represent the standard deviations. Asterisks indicate statistical significance of 1Vif virus infectivity compared
to WT (student t-test p < 0.05). (C) Editing activity of WT and mutant A3G proteins determined by bacterial mutation assay. A deaminase defective E259Q mutant
was used as a negative control. Mock indicates the empty vector control. Error bars represent the standard deviations of two independent experiments. The asterisks
indicate statistical significance compared to WT (student t-test, p < 0.05). (D) Co-immunoprecipitation assays to determine the binding of Vif to the A3G-R122A
mutant. The expression plasmids for the HA tagged A3G or R122A mutant and Vif were co-transfected into HEK293T cells (lane 3 and lane 4, respectively). MG132
proteasome inhibitor was added 12 h before lysing the cells, and A3G was immunoprecipitated with an anti-HA antibody and analyzed by immunoblot with the
indicated antibodies. HA-A3G or Vif expression alone was used as a control for nonspecific binding (lane 1 or lane 2, respectively) (E) Vif-dependent degradation of
A3G mutant, R122A. We co-transfected the expression vector HA-tagged A3G or R122A mutant with (lane 4 or lane 6, respectively) or without Vif expression plasmid
(lane 3 or lane 5, respectively) into HEK293T cells. The amounts of cellular A3G from cells transfected with or without the Vif expressing plasmid were compared by
immunoblot assay using an anti-HA antibody. GFP was used as the indicator for transfection efficiency. The lanes without HA-A3G (lane 1 or 2) are controls for
nonspecific binding to anti-HA antibody.
and Y86A were incorporated into virions to the same extent
as A3G-WT (Figure 4A). In our analysis, the BP of the R24
residue was low based on the soluble A3G-NTD homology
model (Figure 1B). However, R24 is known to contribute to
RNA association (Huthoff et al., 2009). Therefore, we evaluated
the virion incorporation efficiency of R24A (Figure 4A) and
confirmed that the mutation in this residue impaired A3G virion
encapsidation. To control for potential differences in cellular
expression of these mutants, we quantified relative expression
levels based on EYFP signals and found that there was no
difference (Figure 4B).
Construction of an A3G-NTD RNA Docking
Model and Calculation of RNA Contact
Frequency
Our analysis showed that the BP of A3G to RNA estimated by
two-dimensional analysis alone is not sufficient to determine
the A3G-NTD residues responsible for RNA-dependent A3G
packaging. Because the calculation of the BP scores does not
consider geometric relationships, we speculated that additional
structural features, such as spatial distance between putative RNA
binding residues (high BP residues), the innate A3G-NTD RNA
binding surface/bound RNA, and the potential steric hindrance
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FIGURE 4 | Packaging efficiency of A3G mutants into HIV1-1Vif virions. (A) A3G packaging efficiency, and (B) Intracellular EYFP fluorescence intensity are shown as
described in the legend for Figures 2C,D. The asterisks indicate statistical significance compared to WT (student t-test, p<0.05).
due to amino acids orientation could all determine RNA binding.
Therefore, we hypothesized that the potential impact of these
factors is minimized on a local scale and RNA contact frequency
(CF) can be modeled with the docking of short nucleotides.
Recently, York et al. reported about the RNA binding specificity
of A3G (York et al., 2016). However, our current computer-
assisted docking simulation is limited to using non-specific 5-
mer RNA molecules. Therefore, we used an all coarse-grained
molecular dynamics (CGMD) docking simulations on the soluble
A3G-NTD model with a universal sequence of RNA to identify
clusters of binding. We sorted clusters from high to low scores,
and the top five were further investigated (Figure 5A). The
CF of the top five clusters is summarized in Figure 5B and
Supplementary Figure 6. Residue R122, which is spatially close
to W94, mediated direct association with RNA. S28, R30, and
Y124, constituted a cluster involved in RNA interaction. R24 and
I26 located beside R30 also had high-predicted CF (Figure 5B).
On the other hand, both BP and CF values for R29 were similar
to R30 (Figures 1B, 5B). Interestingly, mutation of R29 did not
impede A3G virion encapsidation (Figure 4A). Because of the
proximity of residue R30 to R29, we could not examine the
function of these residues on the basis of the in silico simulations
alone, so more detailed experimental analyses will be needed.
Residue Y86 located on the opposite side of the RNA-associating
surface (Figure 1A) had moderate CF (Figure 5B), suggesting a
minor role in the formation of the RNA-A3G-NTD complex. We
also calculated the CF of each residue on the non-human primate
model, and most residues showed similar patterns to the soluble
form model (Figure 5C and Supplemental Figure 7). However,
the RNA associating residues R24, I26, and R122 had lower CF
in this model (Figure 5C), suggesting that the soluble A3G-NTD
model provides better structural predictions of RNA association.
I26 has been reported to be involved in Vif-interaction and A3G
dimerization (Gorle et al., 2017; Zhai et al., 2017), but it has
not been identified as an RNA associating residue. Both R24
and I26 RNA BPs were predicted to be modest (Figure 1B).
However, these residues are located in the A3G dimerization
surface, which is important for A3G-RNA interaction, suggesting
that they may indirectly contribute to RNA association. Taken
together, residues R24, I26, S28, R30, R122, and Y124 are involved
in the interaction with RNA, actively supporting our A3G-RNA
docking model.
DISCUSSION
Here, we report the utilization of in silico approaches (RNA
binding propensity prediction, flexible RNA docking and
structural modeling) to identify putative RNA-binding residues
in the N-terminal domain (NTD) of A3G. Our model identified
the previously reported RNA-associating hot-spot residues, S28,
R30, R122, and Y124 and we confirmed their involvement
in RNA binding in a series of mutagenesis experiments.
Interestingly, our experimental data confirmed that the I26
residue is an RNA binding determinant as initially predicted
in our model. Although I26 is a known determinant of A3G-
Vif interactions (Gorle et al., 2017), here we report for the first
time that I26 is also involved in RNA binding. In addition to
I26, we also confirmed that the nearby residue R24, which was
previously reported by others to be involved in the association
with several A3G interacting RNAs (Table 1), mediates RNA
interaction (Figure 4A) despite a low BP in our simulation
(Figure 1B). These examples suggest the importance of flexible
RNA docking in addition to BP prediction. Residues with low BP
but located near high-BP regions can act as bridges to facilitate
protein-RNA interactions. Moreover, these residues are located
in the A3G-dimerization surface and their mutation impairs
dimerization and RNA association (Gorle et al., 2017; Zhai
et al., 2017). On the other hand, residue Y86, which showed
high BP (Figure 1B), was located on the opposite side of the
RNA-interaction surface (Figures 1A, 5A) and had moderate CF
(Figure 5B). Experimentally, Y86 did not appear to be involved
in RNA association (Figure 4A). These data highlight an essential
aspect of the RNA-association prediction: residues with low to
moderate BP, but high CF and located near high BP residues can
also be determinants of RNA binding.
Recently Polevoda et al. investigated the competitive
binding of RNA and single-strand DNA (ssDNA) to A3G
(Polevoda et al., 2015). They isolated a number of peptides in
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FIGURE 5 | Structural model of the A3G-NTD with single strand RNA docking. (A) The top five clusters of docked conformations between the surface of A3G-NTD
model based on soluble A3G-NTD and RNA pentamers represented by spheres are shown. The color of the A3G surface shows the BP with the same scale
presented in Figure 1A. (B) Contact frequency (CF) of selected residues from Supplementary Figure 6 calculated by CGMD docking simulation. Box plots show the
mean of CF distribution of ten models of soluble A3G-NTD for the top five clusters. (C) CF of selected residues from Supplementary Figure 7. Column bar graph
shows CF of a single model of non-human primate A3G-NTD.
the A3G domain that bind to RNA, solely or in competition
with ssDNA. They used a cross-linking method to show that
non-specific 25nt RNA binds to A3G in both the N- and
C-terminal domains. The peptides that stood out within the
NTD were aa 15–29, 41–52, 83–99, and 181–194 with only the
last being a ssDNA binding site. In our study, the RNA BP of
most residues corresponding to these peptides was moderate to
low (Figure 1B and Supplementary Figure 1). However, some
of the residues with high BP or CF overlapped: 15–29 contains
S28 and 83–99 contains W94 (Figures 1B, 5B). Interestingly,
all of these residues were located on the surface of the RNA
binding region in our model (Figure 5A) and showed high
CF (Supplementary Figure 6). The peptide corresponding to
residues 181–194 had a low BP but modestly high CF. On the
other hand, the peptide corresponding to residue 41–52, located
on the opposite side of the RNA binding surface, showed both
low BP and CF in our simulations. We speculate that these
discrepancies are due to the increase in conformational flexibility
of the peptides along with the influence of spatially proximate
residues in the docking simulations.
The loss of the A3G-NTD results in a drastic decrease
in DNA binding affinity, although the C-terminal domain of
A3G is responsible for its catalytic activity, and the A3G-
CTD alone is able to bind and deaminate ssDNA (Holden
et al., 2008). A3G-NTD is also considered important for ssDNA
interaction and can greatly enhance the deamination efficiency
(Holden et al., 2008; Chelico et al., 2010). Therefore, we
additionally calculated the BP of each residue in our A3G-NTD
model and performed the A3G-ssDNA docking to estimate CF
(Supplementary Figures 8, 9). The distribution of both BP and
CF for ssDNA binding showed a similar pattern to the ssRNA
association (Table 1), indicating that ssDNA and ssRNA may
interact with the same surface of A3G-NTD. Together, these
data suggest that the conservation of RNA binding affinity in
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the A3G-NTD indirectly contributes to A3G’s HIV-1 ssDNA
deamination activity.
In order to examine the validity of our predictions, we built
a second structural model of the human A3G-NTD based on
the crystal structure of non-human primate A3G-NTD (Xiao
et al., 2016) and performed similar RNA docking simulations.
Generally, the BP and CF profiles of the non-human primate
crystallography model and soluble human A3G model were
similar (Supplementary Figures 1, 2, 6, 7). However, Y86, but
not I26, R24, and R122 were predicted to be involved in RNA
association in their CFs (Figure 5C), but were not experimentally
validated (Figure 4A). These data suggest that the soluble model
is a better template for RNA docking simulation. In this regard,
the template of the soluble model has been recently revealed
by NMR and contains ten snapshots, whereas the non-human
primate model derives from one crystal structure and therefore
has little protein flexibility. Our aaRNA prediction considers
accessibility to the residue: the lower the accessibility, the less
the binding likelihood. Certain RNA binding residues could
be more accessible in some of the soluble A3G models, but
inaccessible in the single crystal structure model. This may
explain the overall better agreement of the soluble model
predictions with the experimental observations. In addition,
the soluble human A3G-NTD has 80% sequence identity to
the wild-type human A3G. On the other hand, though the
non-human primate A3G has 69% sequence identity to the
wild-type human A3G-NTD, the lower sequence identity could
account for some of the experimental discrepancies. The root-
mean-squares-deviation (RMSD) between the soluble and the
non-human primate model was 3.595, indicating not a drastic
but significant difference between these two models. Taken
together, the soluble A3G-NTD model provided the highest
accuracy of RNA association and further refinements of the
non-human primate model are desirable. Nevertheless, all of
the RNA associating residues that we confirmed experimentally
are highly conserved in human and non-human primate A3Gs
(Chimpanzee, Gorilla, Orangutan, Macaque, and African green
monkey) (Zhang and Webb, 2004). This suggests that the
RNA associating surface in the A3G-NTD is highly conserved
across species.
To examine our findings in the context of the state of the
art, we confirmed that residues R122, predicted here to be
involved in the interaction with RNA (Figure 2A) have also
been shown to interact with Vif (Figures 3D,E). Interestingly,
D128 and its surrounding residues, P129 and D130, critical
determinants of the species-specific sensitivity of A3G to Vif,
but do not contribute to virion encapsidation (Bogerd et al.,
2004; Mangeat et al., 2004; Schrofelbauer et al., 2004; Xu et al.,
2004), had modest to low BP and CF in our model (Figures 1B,
5B). Together, the previous reports (Bogerd et al., 2004; Mangeat
et al., 2004; Schrofelbauer et al., 2004; Xu et al., 2004; Zhang
et al., 2010; Letko et al., 2015) and our R122 mutation assay
suggest that the Vif-interacting region of A3G-NTD is close,
but distinct from the RNA-binding interface. Therefore, our
work provides insights to better understanding the structural
nuances of A3G-RNA and Vif binding, subsequently could
aid the in silico design of small molecules that specifically
target the A3G-Vif complex without disrupting the A3G-
RNA binding.
Interestingly, it has been reported that the Vif mediated A3G
inhibition is not only mediated by proteosomal degradation but
also by translational repression (Stopak et al., 2003; Guerrero
et al., 2016). Though it remains unclear how important each of
these pathways are relative to one another in vivo, these findings
suggested that both pathways could be targeted to restore cellular
A3G levels. Inhibiting both pathways could potentially lead to a
more effective, multipronged approach to restoring A3G cellular
levels for packaging. Interestingly, Guerrero et al. demonstrated
that A3G degradation deficient mutant, K26R was still able
to decrease A3G mRNA expression, and concluded that these
two pathways are independent. On the other hand, they also
showed that mutants of certain A3G-binding residues in Vif,
H42 and H43, did not also inhibit A3G translation, suggesting
that the residues in Vif responsible for translational repression
may be partially located in the A3G-Vif interacting domain,
or this function may require A3G-Vif interaction. In either
case, A3G-Vif interaction inhibitors could potentially block both
of Vif ’s A3G inhibitory pathways. In addition, Letko et al.
simulated a docking model of A3G-NTD and Vif, indicating
that A3G β4-α3 loop composed of Y125, D128, and D130 fitted
in the Vif pocket (Letko et al., 2015). In their model, the Vif
residues at position 14–17, 19, and 22 formed one side of the
pocket, and the other side flanked by the residues at 40–44
responsible for A3G translational repression. According to their
docking model, it would be possible to design small molecules
that inhibit both Vif activities against A3G protein expression
and stability.
Naturally occurring non-synonymous changes in the A3G
interaction domains are of clinical importance and could alter
RNA binding. In this regard, Matume et al. recently reported four
non-synonymous polymorphisms (H186R, R256H, Q275E, and
G363R) in the A3G genes in a cohort of HIV-1 infected South
African individuals (Matume et al., 2019). Of these residues, only
H186 is present in the A3G-NTD. With our in silico model,
we found that the residue at position 186 had a low CF score
(Supplementary Figure 6), indicating that it may be less relevant
to RNA association. Future clinical investigations may reveal
other A3G polymorphisms important for the RNA association.
In summary, we applied a novel approach using in silico
models to predict A3G-RNA interaction sites and experimentally
confirmed these predictions. In addition, we utilized the
models to identify a novel residue, I26 that contributes to
RNA association. Together with previous alanine scanning
experiments and structural modeling of Vif docking to A3G,
the RNA interaction predictions described here could be used
for in silico drug screening or design of selective inhibitors of
A3G-Vif binding while maintaining the A3G-RNA association
necessary for virion incorporation.
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Supplementary Figure 1 | RNA-binding propensity (BP) of all residues in the
homology model of human A3G-NTD based on the solution NMR human
A3G-NTD structure (PDBID: 2mzz) predicted by aaRNA. The box plot shows the
distribution of the BP for ten structures.
Supplementary Figure 2 | RNA-binding propensity (BP) of all residues in the
homology model of human A3G-NTD simulated based on the crystal structure of
a non-human primate A3G (PDBID: 5k81).
Supplementary Figure 3 | Raw images of western blot analysis presented in
Figure 3 are shown.
Supplementary Figure 4 | Raw images of western blot analysis presented in
Figure 3D are shown.
Supplementary Figure 5 | Raw images of western blot analysis presented in
Figure 3E are shown.
Supplementary Figure 6 | RNA-contact frequency (CF) of all residues in the
homology model of human A3G-NTD based on the human A3G-NTD solution
NMR structure (PDBID: 2mzz) with 5-mer single strand RNAs calculated by
CGMD docking simulation. The box plots show the distribution of the CF of ten
models with the top five clusters.
Supplementary Figure 7 | RNA-contact frequency (CF) of all residues in the
homology model of human A3G-NTD simulated based on the crystal structure of
a non-human primate A3G (PDBID: 5k81). The column bar graph shows the mean
of the CF of a single model with the top five clusters.
Supplementary Figure 8 | DNA-binding propensity (BP) of all residues in the
homology model of human A3G-NTD based on the human A3G-NTD solution
NMR structure (PDBID: 2mzz) predicted by aaDNA. The box plot shows the
distribution of the BP for ten structures.
Supplementary Figure 9 | DNA-contact frequency (CF) of all residues in the
homology model of human A3G-NTD based on the human A3G-NTD solution
NMR structure (PDBID: 2mzz) with 5-mer single strand DNAs calculated by
CGMD docking simulation. The box plots show the distribution of the CF of ten
models with the top five clusters.
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